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Crystal structure of 6-hydroxymethyl-7,8-dihydropterin
pyrophosphokinase, a potential target for the development 
of novel antimicrobial agents
Bing Xiao1, Genbin Shi2, Xin Chen1, Honggao Yan2* and Xinhua Ji1*
Background: Folate cofactors are essential for life. Mammals derive folates
from their diet, whereas most microorganisms must synthesize folates de novo.
Enzymes of the folate pathway therefore provide ideal targets for the
development of antimicrobial agents. 6-Hydroxymethyl-7,8-dihydropterin
pyrophosphokinase (HPPK) catalyzes the transfer of pyrophosphate from ATP
to 6-hydroxymethyl-7,8-dihydropterin (HP), the first reaction in the folate
biosynthetic pathway.
Results: The crystal structure of HPPK from Escherichia coli has been
determined at 1.5 Å resolution with a crystallographic R factor of 0.182. The
HPPK molecule has a novel three-layered αβα fold that creates a valley
approximately 26 Å long, 10 Å wide and 10 Å deep. The active center of HPPK
is located in the valley and the substrate-binding sites have been identified with
the aid of NMR spectroscopy. The HP-binding site is located at one end of the
valley, near Asn55, and is sandwiched between two aromatic sidechains. The
ATP-binding site is located at the other end of the valley. The adenine base of
ATP is positioned near Leu111 and the ribose and the triphosphate extend
across and reach the vicinity of HP.
Conclusions: The HPPK structure provides a framework to elucidate
structure/function relationships of the enzyme and to analyze mechanisms of
pyrophosphoryl transfer. Furthermore, this work may prove useful in the
structure-based design of new antimicrobial agents.
Introduction
6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase
(HPPK) belongs to a class of enzymes that catalyze
pyrophosphoryl transfer [1]. This class of enzymes also
includes phosphoribosylpyrophosphate synthase, thi-
amine pyrophosphokinase, nucleotide pyrophospho-
kinase and GTP pyrophosphokinase. HPPK catalyzes the
transfer of pyrophosphate from ATP to 6-hydroxymethyl-
7,8-dihydropterin (HP), the first reaction in the folate
biosynthetic pathway (Figure 1). Although the mecha-
nisms of many kinases that catalyze phosphoryl transfer
have been extensively characterized, little is known
about pyrophosphokinases.
Folate cofactors are essential for life [2]. Mammals have
an active-transport system for deriving folates from the
diet. In contrast, most microorganisms must synthesize
folates de novo, because they lack the active-transport
system. Therefore, the folate biosynthetic pathway is an
ideal target for potential antimicrobial agents. Sulfon-
amides that inhibit dihydropteroate synthase (DHPS),
the second enzyme in the folate biosynthetic pathway
(Figure 1), were the first group of synthetic compounds
to be widely used as antibacterial agents and are still in
clinical use [3]. Diaminopyrimidines that inhibit dihydro-
folate reductase (DHFR) are currently used as antibacte-
rial, antiprotozoal and antineoplastic agents [4]. The
combination of sulfamethoxazole (an inhibitor of DHPS)
and trimethoprin (an inhibitor of DHFR) is used to treat
urinary tract, respiratory tract and other bacterial infec-
tions [4,5]. However, the rates of resistance to these
antibiotics have increased dramatically during the past
two decades [5,6]. Bacterial resistance results mainly
from alterations in the target enzymes and is transferred
via plasmids and transposons. The rapid increase in resis-
tance to these and other antimicrobial agents has caused
a worldwide health care crisis [5–9].
HPPK was first identified in Escherichia coli in 1964 [10]
and partially purified in 1969 [11]. Some properties of
HPPK were investigated, including the nature of the reac-
tion (pyrophosphoryl transfer), the Km values for the sub-
strates, and the requirement of Mg2+ for activity. The
enzyme was purified to homogeneity in 1991 [12] and the
gene encoding HPPK was cloned in 1992 [13]. The E. coli
enzyme is homologous to HPPKs from other pathogenic
microbial organisms (Figure 2). For example, it shares
56% amino acid sequence identity with Haemophilus
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influenzae HPPK, 40% identity with Pneumocystis carinii
HPPK and 33% identity with Mycobacterium tuberculosis
HPPK. As a small, thermostable, monomeric protein, 
E. coli HPPK is not only a new target for the development
of antimicrobial agents but also an excellent model system
for studying the mechanisms of pyrophosphoryl transfer.
We have determined the crystal structure of HPPK at 1.5 Å
resolution using the multiwavelength anomalous diffrac-
tion (MAD) technique. The spatial distribution of the 13
conserved residues among 11 HPPKs (Figure 2) indicates
that the active center is located in a valley approximately
26 Å long, 10 Å wide and 10 Å deep. To identify the HP-
and ATP-binding sites, 1H–15N heteronuclear single
quantum coherence (HSQC) NMR spectra of HPPK were
acquired in the absence and presence of ATP or 6-hydrox-
ymethylpterin (a competitive inhibitor of the substrate
HP). A preliminary model of the HPPK–HP–Mg2+–ATP
complex has been built and provides a working hypothesis
to be tested by site-directed mutagenesis and other means.
Results and discussion
Overall structure
The crystal structure of E. coli HPPK at 1.5 Å resolution
was solved using MAD data collected from crystals con-
taining selenomethionine (SeMet). X-ray diffraction data
were measured near the Se K-absorption edge. The
experimental electron-density map is of high quality
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Figure 2
Amino acid sequence alignment of 11 HPPKs.
The numbering and secondary structure
assignments are given for E. coli HPPK. The
dots at the beginning and end of each
sequence indicate N- and C-terminal
truncations, respectively. The internal dots
represent gaps introduced for better sequence
alignment. The amino acid residues that are
conserved among the 11 HPPKs are shown in
bold face. The 11 HPPK sequences are as
follows: ecoli, E. coli; haein, Haemophilus
influenzae; metex, Methylobacterium
extorquens; bacsu, Bacillus subtilis; synsp,
Synechocystis sp.; pneca, Pneumocystis
carinii; helpy, Helicobacter pylori; strpn,
Streptococcus pneumoniae; pissa, pea; yeast;
and myctu, Mycobacterium tuberculosis.
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Figure 1
The folate biosynthetic pathway. The
abbreviations for the enzymes of the pathway
are given: HPPK, 6-hydroxymethyl-7,8-
dihydropterin pyrophosphokinase; DHPS,
dihydropteroate synthase; DHFS,
dihydrofolate synthase; and DHFR,
dihydrofolate reductase.
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Structure
(Figure 3). The structure contains all 158 amino acid
residues of the polypeptide chain (Figure 4) and 236
water molecules. The crystallographic R factor is 0.182 for
all reflections within the resolution range 20.0–1.5 Å
(Table 1). HPPK has a three-layered αβα fold formed by
six β strands and four α helices in the sequence β1-α1-β2-
β3-α2-β4-β5-β6-α3-α4 (Figure 5a). In the center of the
protein, the six β strands are organized into an antiparallel
β sheet (β2, β3, β1 and β4) and a β hairpin (β6 and β5).
The angle between the adjacent strands β4 and β6 is
~70°. On each side of the central β structure there are two
α helices. No such three-layered αβα fold has been found
in topological searches. Instead, similar folds have been
found when the search is carried out separately with two
motifs: the N-terminal motif (β1-α1-β2-β3-α2-β4) and
the C-terminal motif (β5-β6-α3-α4). The best fits of
these motifs are superimposed on HPPK in Figure 5b.
The N-terminal motif of HPPK shares a two-layered αβ
fold with the ribosomal protein S6 (rpS6) [14]. The
topology of the C-terminal motif of HPPK mimics that 
of the glucocorticoid receptor DNA-binding domain
(grDBD; Figure 5b) [15]. Both rpS6 and grDBD are pro-
teins that interact with nucleic acids. When rpS6 and
grDBD are superimposed with HPPK, their nucleic acid
interaction sites face each other across the valley of
HPPK (Figures 5b and c). The valley appears to contain
both ATP- and HP-binding sites (see below). This
observation implies that rpS6 and grDBD might be the
ancestral origin in the evolution of HPPK, although the
sequence identity is as low as 10% between the HPPK
N-terminal motif and rpS6 and only 5% between its 
C-terminal motif and grDBD. Four 310 helices and two
consecutive turns are found in the loops of HPPK. The
long loops β2–β3 and α2–β4 are mobile, as indicated by
the higher than average temperature factors. The struc-
tural motif β1-loop-α1 (residues 8–15) assumes two dis-
tinct conformations (Figure 4) with a population ratio of
0.54:0.46 (see Materials and methods section).
Location of the active center
The fold of the HPPK molecule creates a valley that is
approximately 26 Å long, 10 Å wide and 10 Å deep
(Figure 5c). The valley starts from a V-shaped cleft
between β6 and the continuing loop (residues 110–116),
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Figure 3
MAD map of HPPK. The high quality experimental electron density
from MAD phasing, contoured at 1σ, superimposed on the final
structure. The map is shown in cyan and the model is colored
according to atom type: carbon, yellow; nitrogen, blue; oxygen red;
sulfur, green. (The figure was prepared using the program O [21].)
Figure 4
Stereoview of the Cα backbone trace of
HPPK from E. coli. Selected residues and the
N and C termini of the polypeptide chain are
labeled. The polypeptide chain comprising
residues 9–15 assumes two conformations
(see text). (The illustration was prepared using
the program MOLSCRIPT [30].) 20
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Structure
runs along the α2 helix and across the face of the four-
stranded β sheet, and ends at the C-terminal loop. Three
flexible loops, β2–β3 (residues 43–53 with higher than
average temperature factors), β1–α1 (residues 8–15 with
two conformations) and α2–β4 (residues 82–92 with
higher than average temperature factors), form one wall of
492 Structure 1999, Vol 7 No 5
Table 1
Summary of the crystal structure determination and refinement of HPPK.
MAD (SeMet)
Native λ1 (Edge) λ2 (Peak) λ3 (Remote 1) λ4 (Remote 2)
Data collection statistics
Wavelength (Å) 0.9800 0.9792 0.9788 0.9686 0.9870
Resolution (Å) 1.5 1.6 1.6 1.6 1.6
Measured reflections 132,018 75,584 75,321 75,618 75,056
Unique reflections 23,352 19,127 19,133 19,125 19,086
Completeness (%) 95.8 99.8 99.8 99.8 99.6
Rmerge* 0.050 0.047 0.049 0.044 0.040
MAD phasing statistics
Se sites 4 4 4 4
Differences – f′′ f′(λ3–λ1) f′(λ4–λ1)
Phasing power† – 2.83 2.49 2.27
Figure of merit – 0.385 0.407 0.389
Overall figure of merit 0.655 (0.886)‡
Refinement statistics
Nonhydrogen atoms
protein 1267
solvent 236
total/asymmetric unit 1503
Crystallographic R factor§
all data 0.182
I>2σ(I) 0.174
Rms deviations (Å)
bond distances (Å) 0.008
angle distances (Å) 0.024
*Rmerge = Σ|(I–<I>)| / Σ(I), where I is the observed intensity.
†Phasing power = frms/Erms, where frms = [(ΣfH2/n]½ and
Erms = [Σ(FPH–|FP + fH |2 /n]½, where fH is the calculated structure
factor of the heavy atom, FPH is the observed structure factor of the
heavy-atom derivative and FP is the observed structure factor of the
wild-type crystal. ‡Value after density modification. §Crystallographic
R factor = Σ| |Fo|–|Fc| |/ Σ|Fo|, where Fo and Fc are the observed and
calculated structure factors, respectively.
Figure 5
The protein fold of HPPK. (a) The secondary structure assignment and
fold of HPPK. The α helices are represented as cyan spirals, β strands
as yellow arrows and loops as red pipes. (b) Superposition of HPPK
with rpS6 [14] and grDBD [15]. HPPK is shown in red, rpS6 in cyan
and grDBD in yellow. (Figures (a) and (b) were prepared using
Raster3D [31].) (c) The van der Waals surface representation of
HPPK. The surface is colored according to electrostatic potential: blue
for positive and red for negative. (The figure was prepared using the
program GRASP [32].)
the valley (Figures 5a and c). The other wall of the valley
is relatively rigid and is constructed by the structural motif
β6-loop-α3 (Figures 5a and c), where residues Val113,
Pro114, Met118, Met124, Leu125, Trp126, Pro127,
Leu128 and Phe129 participate in the formation of the
hydrophobic core of the protein (Figures 2 and 3). Among
the 11 HPPK sequences, there are 13 strictly conserved
residues (Gly8, Asn10, Gln50, Asn55, Glu77, Arg82,
Arg92, Asp95, Asp97, Leu111, Pro114, His115 and Arg121;
Figure 2) which are located in three regions of the valley.
The flexible wall contains Gly8, Asn10, Gln50, Arg82 and
Arg92, whereas Leu111, Pro114 and His115 are located in
the rigid wall. Arg121, Asn55, Glu77, Asp95 and Asp97
reside in the bottom of the valley, among which Glu77,
Asp95 and Asp97 cluster in the middle portion of the
bottom, resulting in an area with concentrated negative
charge (Figures 5c and 6). Therefore, the valley 
is most likely to form the active center where the two 
substrates (ATP and HP) and Mg2+ bind.
ATP- and HP-binding sites 
Sequential resonance assignments of unliganded HPPK
and its complex with magnesium adenylyl (β,γ-methyl-
ene)diphosphonic acid have been achieved by three-
dimensional double and triple resonance spectroscopy
using uniformly 15N- and 15N/13C-labeled HPPK samples.
The analysis included three-dimensional HNCACB,
CBCA(CO)NH, HCCH-TOCSY (HCCH total correla-
tion spectroscopy) and 15N-edited nuclear Overhauser
effect spectroscopy (NOESY) HSQC experiments. The
sequential resonance assignments were also assisted and
confirmed by selective 15N labeling (GS, J Gao and HY,
unpublished data). To identify the binding sites for ATP
and HP, the 1H-15N HSQC NMR spectra of HPPK were
obtained in the presence and absence of ATP or 
6-hydroxymethylpterin. The binding of 6-hydroxy-
methylpterin caused significant changes in the chemical
shifts of ~15% for the backbone amide resonances
(Figure 7a). Of these backbone amides, most are localized
in a region that contains the conserved residue Asn55 and
the rest are localized in a region that contains the con-
served residue Leu111 (Figure 7c). Therefore, the region
of the valley that contains Asn55 is most likely to be the
binding site for the substrate HP. Because 6-hydrox-
ymethylpterin also binds to the ATP site, but with a
much lower affinity than to the HP site (GS and HY,
unpublished results), the region of the valley that con-
tains the conserved residue Leu111 is  considered most
likely to form the binding site for ATP. Indeed, the
binding of ATP caused significant changes in the chemi-
cal shifts of many backbone resonances in this region
(Figures 7b and d). Surprisingly, the binding of ATP also
caused significant changes in the chemical shifts of many
backbone amide resonances in the tentative HP-binding
site. Because ATP has only one binding site in HPPK
(GS and HY, unpublished results), the chemical shift
changes of the residues in the HP-binding site are proba-
bly due to conformational changes induced by the
binding of ATP.
Model of  the HPPK–HP–Mg2+–ATP complex
On the basis of the crystal structure of E. coli HPPK and
the results of NMR experiments, a ground-state model of
the HPPK–HP–Mg2+–ATP complex was constructed
(Figure 6). The HP molecule is sandwiched between the
aromatic rings of Tyr53 and Phe123; the conserved residue
Asn55 is potentially able to form hydrogen bonds with the
HP molecule. The hydroxymethyl group of HP is in the
vicinity of the carboxylate group of Asp95 and the β- and
γ-phosphoryl groups of ATP. The Mg2+ is surrounded by
Glu77, Asp95, Asp97 and the β- and γ-phosphoryl groups
of ATP. Two conserved residues His115 and Arg121 form
hydrogen bonds to both α- and γ-phosphoryl oxygen
atoms. The ribose moiety is exposed to the solvent, and
the adenine base is wedged in the V-shaped cleft near the
conserved residue Leu111. The HPPK–HP–Mg2+–ATP
complex provides a framework for further studies to eluci-
date the mechanism of HPPK catalysis.
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Figure 6
Model structure of the ground state HPPK–HP–Mg2+–ATP complex.
HPPK is illustrated as a space-filling model with the ‘shapely’ color
scheme of Raster3D (i.e. residues colored by type). HP and ATP are
drawn as stick models and colored according to atom type: carbon in
light gray, nitrogen in blue, oxygen in red and phosphorus in yellow.
The Mg2+ ion is shown as a purple sphere. The labels highlight the
cofactor, substrates and important residues. (The figure was prepared
using Raster3D [31].)
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Structure
Superposition of the 1H—15N HSQC spectrum of free HPPK with
that obtained in the presence of (a) 6-hydroxymethylpterin and (b)
ATP. The HSQC peaks of free HPPK are in black and those of HPPK
with bound 6-hydroxymethylpterin or ATP are in red. The HSQC
peaks that are significantly shifted upon binding with
6-hydroxymethylpterin or ATP are labeled. The positions of the Cα
atoms of these amino acid residues are shown in red in (c) and (d),
corresponding to (a) and (b), respectively. The sidechains of
residues that are conserved among the 11 HPPK sequences are
shown in ball-and-stick form in (c) and (d).
Biological implications
As mammals derive folates from their diet but most
microorganisms must synthesize folates de novo, enzymes
in the folate biosynthetic pathway are ideal targets for
developing antimicrobial agents. The first synthetic com-
pounds to be widely used for treating bacterial infections
were sulfonamides, inhibitors of dihydropteroate synthase
(DHPS) in the folate biosynthetic pathway. Sulfonamides
and trimethoprim (an inhibitor of dihydrofolate reductase
[DHFR] another enzyme of the folate pathway) are still
widely used for treating many infectious diseases. Co-
trimoxazole, a combination of sulfamethoxazole (an
inhibitor of DHPS) and trimethoprin, remains the stan-
dard therapy for Pneumocytis carinii pneumonia, a major
cause of mortality in AIDS patients [16]. During the past
two decades, however, the rates of resistance to these
antibiotics have increased dramatically [5,6]. This rapid
increase in antibiotic resistance has rendered these and
many other antibiotics ineffective for treating infectious
diseases and caused a worldwide health care crisis. New
antimicrobial agents are therefore needed urgently.
6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase
(HPPK) catalyzes the transfer of pyrophosphate from
ATP to 6-hydroxymethyl-7,8-dihydropterin, the first
reaction in the folate biosynthetic pathway. HPPK is,
therefore, an attractive target for the development of
new antimicrobial agents. Because of its small size and
thermostability, Escherichia coli HPPK also provides an
excellent model system for studying the mechanisms of
enzymatic pyrophosphoryl transfer.
In this study, we have determined the crystal structure
of E. coli HPPK at 1.5 Å resolution — the first reported
three-dimensional structure for any pyrophosphokinase.
The structure reveals a novel three-layered αβα fold that
creates a valley of approximately 25 Å long, 10 Å wide
and 10 Å deep. The locations of 13 conserved residues in
11 HPPKs indicate that the active center of the enzyme
is located in the valley. The substrate-binding sites of
HPPK have been identified with the aid of NMR
spectroscopy. A model of the HPPK–HP–Mg2+–ATP
complex has been built on the basis of the crystal struc-
ture and the NMR data. The model provides the first
structural framework for elucidating the structure/func-
tion relationships of HPPK and the mechanisms of
pyrophosphoryl transfer. Our study provides the critical
information required for the structure-based design of
HPPK inhibitors that may become new antimicrobial
agents for fighting the worldwide antibiotic crisis.
Materials and methods
Expression of SeMet HPPK and crystallization
The cloning, over-expression and purification of HPPK will be
described elsewhere. To make SeMet HPPK, the E. coli strain CT13,
which is auxotrophic for methionine, was transformed with the expres-
sion vector for HPPK. A single colony of the transformed cells was
used to inoculate 10 ml of Luria broth (LB) medium containing 1 mg
ampicillin. The culture was grown overnight at 37°C and used to inocu-
late 1 L of a medium containing 100 mg ampicillin, 10 mg SeMet and
other nutrients prepared according to a published protocol [17] and
incubated at 37°C with vigorous shaking. When the OD600 of the
culture reached 0.8, isopropyl-1-thio-β-D-galactopyranoside (IPTG) was
added to a final concentration of 0.33 mM. The cells were harvested by
centrifugation 6 h after the addition of IPTG. Crystals of both native and
SeMet HPPK were grown in hanging drops of 5 mg/ml protein over
30% polyethylene glycol (PEG) 4000 in 0.2 M Tris buffer (pH 8.5) at
room temperature. It was critical that the protein was freshly purified
and concentrated before the crystallization experiments.
Data collection, processing and crystal structure determination
MAD phasing was used to solve the crystal structure (Table 1). Native
and MAD data were collected at beamline X9B of the National Syn-
chrotron Light Source, Brookhaven National Laboratory on a Mar-
Research image-plate system at cryogenic temperatures (95K for the
wild-type and 110K for the SeMet crystal) maintained with an Oxford
cryosystem. Four energies near the K-absorption edge of Se were
selected corresponding to the edge (λ1), peak (λ2) and two remote
wavelengths (λ3 and λ4). The native crystal diffracted to 1.5 Å and the
SeMet crystal to 1.6 Å. X-ray data were processed using HKL2000
[18]. The crystal belongs to space group P21 with unit-cell dimensions
a = 36.32, b = 51.98, c = 41.49 Å and β = 110.12º. The asymmetric
unit contains one molecule and the crystal contains ~30% solvent.
The positions of four Se atoms were obtained using the difference
Patterson method with the program package PHASES [19]. A pseudo
multiple isomorphous replacement approach was used to refine the
Se positions and to calculate the phase angles [19]. Wavelength
λ1(edge) was used as ‘native’ and the rest as ‘derivatives’. The result-
ing phases were improved using a density modification procedure,
DM [20]. The electron-density map was of high quality (Figure 3)
except for the regions of the two long loops, β2–β3 (residues 45–50)
and α2–β4 (residues 84–91) (Figure 3). Tracing and model building
were carried out with the program O [21]. The programs X-PLOR [22]
and SHELXL-97 [23] were used to refine the structure at 1.5 Å in two
stages. The first stage was monitored using an Rfree calculated for
10% of the data that were excluded from the refinement. The peptide
chain containing residues 8–15 was built with two distinct conforma-
tions based on the difference electron densities. The two conforma-
tions were assigned equal possibilities and subsequently refined to a
0.54:0.46 ratio. Residues 45–47 in the loop between strands β2 and
β3 were not included due to the lack of electron density. The last
recorded Rfree value was 0.266 and the crystallographic R factor was
0.198 when the model contained 155 residues and 179 water mol-
ecules. In the second stage of refinement, all reflections were
included. The difference electron density for the three missing
residues was significantly improved and the model was completed.
The final model contains all 158 amino acid residues of E. coli HPPK
and 236 water molecules. The secondary structure was assigned with
the program DSSP [24] and the topological searches were carried
out using DALI [25] and TOPS [26]. The structure was assessed
using PROCHECK [27] and showed that 92% of the residues are in
the most favored regions of the Ramachandran plot and no residues
fall into disallowed regions.
NMR spectroscopy
Two-dimensional 1H–15N HSQC NMR spectra of HPPK were
obtained in the presence and absence of ATP or 6-hydroxy-
methylpterin. Uniformly 15N-labeled HPPK was produced by growing
the E. coli strain BL21(DE3) containing the expression construct for
HPPK in M9 medium with 15NH4Cl as the sole nitrogen source. NMR
samples were prepared by dissolving lyophilized HPPK in 20 mM
sodium phosphate pH 7.4 (pH meter reading without correction for
isotope effects) in H2O/2H2O(9/1). The unliganded HPPK sample
contained 1.6 mM HPPK. The complex samples contained 1.2 mM
HPPK and 4 mM 6-hydroxymethylpterin or 15 mM ATP. Two-dimen-
sional 1H–15N HSQC spectra [28,29] were acquired at 25°C on a
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Varian INOVA-600 spectrometer with coherent selection by pulsed-
field gradients and sensitivity enhancement.
Molecular modeling
Molecular modeling of the HPPK–HP–Mg2+–ATP complex was carried
out with the programs O [21] and X-PLOR [22] in two steps. Firstly,
two substrate molecules and the metal ion were manually built into the
position suggested by the overall shape of the molecule, the location of
the conserved residues, and the NMR spectra. Water molecules that
conflicted with HP, Mg2+ and ATP were removed. Secondly, the conju-
gate gradient method [22] was utilized to optimize the geometry and to
minimize the energy of the complex. The initial total energy of the
complex was 2582 kcal/mol, and the energy minimization converged
after 250 cycles with a final total energy of –1481 kcal/mol. The rms
deviation for all Cα atoms between the initial and optimized models
was 0.20 Å.
Accession numbers
The coordinates for the structure of E. coli HPPK have been deposited
in the Protein Data Bank with the accession code 1hka.
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